Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, double-blind, fixed-dose, long-term extension trial of the safety of asenapine using olanzapine as an active control in subjects diagnosed with schizophrenia who completed protocol-P05688.

Trial Profile

A multicenter, double-blind, fixed-dose, long-term extension trial of the safety of asenapine using olanzapine as an active control in subjects diagnosed with schizophrenia who completed protocol-P05688.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 May 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Asenapine (Primary) ; Olanzapine
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Actavis; Forest Laboratories; Merck Sharp & Dohme
  • Most Recent Events

    • 26 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 04 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 20 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top